Search

Displaying results 2641 - 2650 of 10000 in total
  1. Target

    Low affinity immunoglobulin gamma Fc region receptor II-a

    go.drugbank.com/bio_entities/BE0002098
    TargetHumans

    Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-a
  2. Target

    Transient receptor potential cation channel subfamily V member 2

    go.drugbank.com/bio_entities/BE0009158
    TargetHumans

    Calcium-permeable, non-selective cation channel (PubMed:10201375). Seems to be regulated, at least in part, by growth factors, such as IGF1, PDGF and morphogenetic neuropeptide/head activator. May transduce physical stimuli in mast cells...

    Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1
  3. Target

    Ankyrin repeat and protein kinase domain-containing protein 1

    go.drugbank.com/bio_entities/BE0009411
    TargetHumans

    Polypeptides: Ankyrin repeat and protein kinase domain-containing protein 1
  4. Target

    Transient receptor potential cation channel subfamily M member 3

    go.drugbank.com/bio_entities/BE0009808
    TransporterHumans

    Suggested to function as an ionotropic steroid receptor in beta-cell, indeed pregnenolone sulfate leads to Ca(2+) influx and enhanced insulin secretion.

    Polypeptides: Transient receptor potential cation channel subfamily M member 3Synonyms: Long transient receptor potential channel 3
  5. Drug

    Linagliptin

    go.drugbank.com/drugs/DB08882
    ApprovedInvestigational

    Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050

    Categories: DPP-IV Inhibitors, Drugs Used in Diabetes
  6. Drug

    Nerofe

    go.drugbank.com/drugs/DB14786
    Investigational

    Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

  7. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.

    Synonyms: IL-1 TRAP, IL-1-TRAPCategories: Receptors, Interleukin-1 Type I, Interleukin-1 Receptor Accessory Protein
  8. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … It has been canceled and withdrawn from the market since August 12, 1997.[L1113]

  9. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a placebo). … GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  10. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    Nonivamide is found in herbs and spices. It is an alkaloid from the Capsicum species. … Nonivamide is a flavoring ingredient. Nonivamide is an organic compound and a capsaicinoid. It is an amide of pelargonic acid and _vanillylamine_.